Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jun 17:15:1600746.
doi: 10.3389/fcimb.2025.1600746. eCollection 2025.

A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant Klebsiella pneumoniae versus Escherichia coli

Jiali Wang #  1   2 , Jia Liu #  3 , Qingsong Lin  1   2 , Fengkui Zhang  1   2 , Yizhou Zheng  1   2 , Zhijian Xiao  1   2 , Jianxiang Wang  1   2 , Aiming Pang  1   2 , Yi He  1   2 , Erlie Jiang  1   2 , Sizhou Feng  1   2 , Mingzhe Han  1   2 , Weihua Zhai  1   2
Affiliations
Comparative Study

A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant Klebsiella pneumoniae versus Escherichia coli

Jiali Wang et al. Front Cell Infect Microbiol. .

Abstract

Introduction: Carbapenem-resistant Enterobacterales (CRE) bloodstream infections (BSI) represent a frequent and grave complication among hematological patients, whose prevailing culprits are Carbapenem-Resistant Klebsiella pneumoniae (CRKP) and Escherichia coli bacteremia (EC). Nevertheless, there is a paucity of studies that have undertaken a comparative analysis of clinical outcomes in patients afflicted with CRKP and EC.

Methods: This study was conducted with the aim of identifying the microbiological and clinical characteristics of hematological patients suffering from bacteremia caused by CRKP and CREC.

Results: The cohort included 90 patients with equal proportions of CRKP BSI and CREC BSI from 2017 to 2022. Among the tested CRE strains (n = 45) for carbapenemase (CP) genes, the KPC gene was most commonly found in CP-CRKP isolates (12/21), while the NDM gene predominated among CP-CREC strains (18/24). A comparison of drug susceptibility showed that CREC was significantly more susceptible to tigecycline than CRKP (97.73% vs. 64.86%, P = 0.018). Patients treated with tigecycline-based therapy had a higher survival rate in the CREC group (18/24,75%) compared to the CRKP group (8/14,57.1%). The CRKP group had a significantly lower rate of prior cephalosporin use within 30 days compared to the CREC group (27% vs. 49%, P = 0.03) and a higher incidence of multi-site infections before BSI (44% vs. 8.9%, P<0.001). Multivariate analysis showed that BSI caused by CRKP was an independent risk factor for survival (P = 0.029), while CAZ-AVI-based therapy emerged as an independent factor improving patient prognosis (P =0.013).

Conclusions: Our results found that bacteremia instigated by CRKP was associated with a less favorable prognosis when compared to cases induced by CREC. Moreover, treatment regimens incorporating CAZ-AVI have the potential to enhance the prognosis of patients grappling with CRE BSI.

Keywords: bacteremia; carbapenem resistant Escherichia coli; carbapenem-resistant Klebsiella pneumoniae; clinical outcomes; hematological patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Participant flow diagram.
Figure 2
Figure 2
Thirty mortality rates by time from blood collection to appropriate therapy, ceftazidime/Avibactam-based therapy, and other active antibiotics. Other active antibiotics refer to antimicrobial agents that were active in vitro against the isolates, except for ceftazidime-avibactam.
Figure 3
Figure 3
Kaplan-Meier curve of the 30-day survival probability of all patients with CRE BSI (A) patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) or carbapenem-resistant Escherichia coli (CREC) bacteria. (B) patients with ceftazidime-avibactam (CAZ-AVI) based therapy or non-ceftazidime-avibactam-based (Non-CAZ-AVI) therapy.
See this image and copyright information in PMC

References

    1. Adeolu M., Alnajar S., Naushad S., Gupta R. S. (2016). Genome-based phylogeny and taxonomy of the 'Enterobacteriales': proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Int. J. Syst. Evol. Microbiol. 66, 5575–5599. doi: 10.1099/ijsem.0.001485 - DOI - PubMed
    1. Bodendoerfer E., Keller P. M., Mancini S. (2019). Rapid identification of NDM-, KPC-, IMP-, VIM- and OXA-48-like carbapenemase-producing Enterobacteriales from blood cultures by a multiplex lateral flow immunoassay. J. Antimicrob. Chemother. 74, 1749–1751. doi: 10.1093/jac/dkz056 - DOI - PubMed
    1. Chen L., Han X., Li Y., Li M. (2021). Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant enterobacterales. Antimicrob. Agents Chemother. 65, e0069821. doi: 10.1128/aac.00698-21 - DOI - PMC - PubMed
    1. Chen J., Xiang Q., Wu J. Y., Huang X. B., Wang C., Wei D. Q., et al. (2022). Different Effects of Antibiotics on Klebsiella pneumoniae and Escherichia coli Resistance Induced by Antibiotics: A Retrospective Study from China. Microb. Drug Resist. 28, 660–669. doi: 10.1089/mdr.2021.0326 - DOI - PMC - PubMed
    1. Davido B., Fellous L., Lawrence C., Maxime V., Rottman M., Dinh A. (2017). Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in enterobacteriaceae and pseudomonas aeruginosa. Antimicrob. Agents Chemother. 61. doi: 10.1128/aac.01008-17 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources